Genotypic screening of the main opiate-related polymorphisms in a cohort of 139 sickle cell disease patients

American Journal of Hematology

Volumn 87, Issue 5, 2012, Pages 534-536

  Joly, Philippe ^a,b   Gagnieu, Marie Claude ^a   Bardel, Claire ^a   Francina, Alain ^a   Pondarre, Corinne ^a   Martin, Cyril ^b  

^a UNIVERSITÉ LYON 1   (France)

^b UNIVERSITÉ DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL METHYLTRANSFERASE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; GLUCURONOSYLTRANSFERASE 2B7; MORPHINE; MU OPIATE RECEPTOR; MULTIDRUG RESISTANCE PROTEIN 1;

ANALGESIA; CHILD; DRUG MECHANISM; DRUG METABOLISM; GENE; GENE FREQUENCY; GENETIC SCREENING; GENOTYPE; HAPLOTYPE; HOMOZYGOSITY; HUMAN; LETTER; MAJOR CLINICAL STUDY; OPRM1 GENE; PAIN; PRIORITY JOURNAL; SICKLE CELL ANEMIA; SINGLE NUCLEOTIDE POLYMORPHISM;

AFRICAN CONTINENTAL ANCESTRY GROUP; ANEMIA, SICKLE CELL; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; CATECHOL O-METHYLTRANSFERASE; CODEINE; COHORT STUDIES; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; DRUG RESISTANCE; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC TESTING; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS; MORPHINE; NARCOTICS; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, OPIOID, MU;

EID: 84859887815     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23137     Document Type: Letter

References (24)

1. Klepstad P, Rakvag TT, Kaasa S, et al. The 118 A > G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand 2004; 48: 1232-1239.
2. Rakvag TT, Klepstad P, Baar C, et al. The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain 2005; 116: 73-78.
3. Darbari DS, Minniti CP, Rana S, van den Anker J. Pharmacogenetics of morphine: Potential implications in sickle cell disease. Am J Hematol 2008; 83: 233-236.
4. Ballas SK, Eckman JR. Sickle cell pain: Biology, etiology, and treatment. In: Editor: Cambridge University-Press (New-York). Disorders of Hemoglobin: Genetics, Pathophysiology and Clinical Management. 2009. pp 497-524.
5. Thorn CF, Klein TE, Altman RB. Codeine and morphine pathway. Pharmacogenet Genomics 2009; 19: 556-558.
6. Tran A, Jullien V, Alexandre J, et al. Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clin Pharmacol Ther 2006; 79: 570-580.
7. Darbari DS, van Schaik RH, Capparelli EV, et al. UGT2B7 promoter variant -840G>A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease. Am J Hematol 2008; 83: 200-202.
8. Duguay Y, Baar C, Skorpen F, Guillemette C. A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity. Clin Pharmacol Ther 2004; 75: 223-233.
9. Gaedigk A, Simon SD, Pearce RE, Bradford LD, et al. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 2008; 83: 234-242.
10. Johansson I, Lundqvist E, Bertilsson L, et al. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993; 90: 11825-11829.
11. Wang D, Johnson AD, Papp AC, et al. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics 2005; 15: 693-704.
12. Campa D, Gioia A, Tomei A, et al. Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther 2008; 83: 559-566.
13. Meineke I, Freudenthaler S, Hofmann U, et al. Pharmacokinetic modelling of morphine, morphine-3-glucuronide and morphine-6-glucuronide in plasma and cerebrospinal fluid of neurosurgical patients after short-term infusion of morphine. Br J Clin Pharmacol 2002; 54: 592-603.
14. Kim RB, Leake BF, Choo EF, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001; 70: 189-199.
15. Kroetz DL, Pauli-Magnus C, Hodges LM, et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 2003; 13: 481-494.
16. Skarke C, Darimont J, Schmidt H, et al. Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers. Clin Pharmacol Ther 2003; 73: 107-121.
17. Reyes-Gibby CC, Shete S, Rakvag T, et al. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain 2007; 130: 25-30.
18. Ware RE, Despotovic JM, Mortier NA, et al. Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia. Blood 2011; 118: 4985-4991.
19. Willson TM, Kliewer SA. PXR, CAR and drug metabolism. Nat Rev Drug Discov 2002; 1: 259-266.
20. Lotsch J, Geisslinger G. Current evidence for a genetic modulation of the response to analgesics. Pain 2006; 121: 1-5.
21. Kirchheiner J, Schmidt H, Tzvetkov M, et al. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J 2007; 7: 257-265.
22. Steen VM, Molven A, Aarskog NK, Gulbrandsen AK. Homologous unequal cross-over involving a 2.8 kb direct repeat as a mechanism for the generation of allelic variants of human cytochrome P450 CYP2D6 gene. Hum Mol Genet 1995; 4: 2251-2257.
23. Allendorf FW, Luikart G. Random mating populations: Hardy-Weinberg principle. Editor: Blackwell Publishing (Malden, MA, USA). Conservation and the genetics of populations. 2007. pp 93-112.
24. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001; 68: 978-989.